LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (the "Company†) (Nasdaq: SVRA), a clinical- stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has received the Day 74 Letter from the FDA which indicated that an Advisory Committee meeting is not planned for the MOLBREEVI Biologics License Application (BLA) and the review is ongoing with a Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2026. Additionally, the Company recently submitt. ...